Positive and negative AIT trials: What makes the difference?
- 26 Downloads
Allergen immunotherapy has proven to be efficacious in allergic rhinitis and asthma. However, results from randomised clinical trials may vary substantially. Clinical trials may unexpectedly fail. The purpose of this review is to discuss the possible factors that may contribute to a successful or unsuccessful study.
Descriptive review exploring the possible causes of negative outcomes in allergen immunotherapy trials.
A series of factors may lead to negative results. Among of these are underpowering of the study, low allergen content in tested extracts, insufficient allergen exposure during monitoring and recruitment of inappropriate patients. In addition, the choice of the primary endpoint may be critical.
A clinical trial aims to evaluate the efficacy of an agent. However, studies with potential effective compounds may fail because of methodical issues. Sometimes, they are the cause of discrepancies between successful phase II and unsuccessful phase III trials. To understand more about failure of studies, investigators and editors should be encouraged to publish negative trials.
Schlüsselwörterallergen immunotherapy randomised clinical trial endpoints negative study phase II trial phase III trial
Consolidated standards of reporting trials
Grass SLIT tablet asthma prevention
House dust mite
Preventive allergy treatment
Randomised clinical trial
Randomised controlled trial
Total combined symptom score
- 6.Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;https://doi.org/10.1002/14651858.cd001936.pub2Google Scholar
- 9.Bousquet PJ, Calderon MA, Demoly P, Larenas D, Passalacqua G, Bachert C, et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011;127:49–56.e11CrossRefGoogle Scholar
- 15.Kleine-Tebbe J, Walmar M, Bitsch-Jensen K, Decot E, Pfaar O, de Rojas DH, et al. Negative clinical results from a randomised, double-blind, placebo-controlled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose-dependent immunological response. Clin Drug Investig 2014;34:577–86CrossRefGoogle Scholar
- 29.Normansell R, Kew KM, Bridgman AL. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev 2015; https://doi.org/10.1002/14651858.cd011293.pub2Google Scholar
- 35.Niederberger V, Neubauer A, Gevaert P, Zidarn M, Worm M, Aberer W, et al. Safety and efficacy of immunotherapy with the recombinant B cell epitope-based grass pollen vaccine BM32. J Allergy Clin Immunol 2018; https://doi.org/10.1016/j.jaci.2017.09.052Google Scholar
- 36.Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA 2017;318:1798–809CrossRefGoogle Scholar
- 37.Technologies D. Results of phase III clinicical trial in peanut allergic children four to 11 years of age. 2017. https://media.dbv-technologies.com/d286/ressources/_pdf/5/4257-PR-PEPITES-topline-results-FINAL.pdf. Accessed 25 Feb 2018Google Scholar
- 39.Circassia. Cat allergy phase III study June 2016 final. 2016. http://www.circassia.com/wp/wp-content/uploads/2016/06/CIR_Cat-allergy-phase-III-results_June-2016-final.pdf. Accessed 25 Feb 2018
- 41.Circassia. Circassia announces top-line results from house dust mite allergy field study. 2017. http://www.circassia.com/media/press-releases/circassia-announces-top-line-results-from-house-dust-mite-allergy-field-study/. Accessed 25 Feb 2018
- 42.Dynavax. Dynavax reports interim TOLAMBA TM ragweed allergy results from DARTT trial 2007. 2007. http://investors.dynavax.com/releasedetail.cfm?releaseid=230979 (Created 23 Feb 2007). Accessed 25 Feb 2018